| Market cap | $846.13M |
|---|---|
| Enterprise value | $680.04M |
| Revenue | $136.735M |
|---|---|
| EBITDA | $10.811M |
| Income | -$17.92 |
| Revenue Q/Q | -11.06% |
| Revenue Y/Y | -2.81% |
| P/E | N/A |
|---|---|
| Forward P/E | 56.75 |
| EV/Sales | 4.97 |
| EV/EBITDA | 62.90 |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 6.19 |
| P/FCF | N/A |
| Price/Book | 4.47 |
| Book/Share | 1.67 |
| Cash/Share | 0.34 |
| FCF yield | -4.55% |
| Volume | 580.433k / 840.500k |
|---|---|
| Relative vol. | 0.69 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -80.00% |
| Est. EPS Q/Q | -100.00% |
| Profit margin | 0.38% |
|---|---|
| Oper. margin | -12.11% |
| Gross margin | 21.09% |
| EBIT margin | -13.14% |
| EBITDA margin | 7.91% |
| Ret. on assets | -3.97% |
|---|---|
| Ret. on equity | -9.63% |
| ROIC | 1.05% |
| ROCE | -7.73% |
| Debt/Equity | 1.38 |
|---|---|
| Net debt/EBITDA | 59.39 |
| Current ratio | 0.46 |
| Quick ratio | 0.31 |
| Volatility | 6.41% |
|---|---|
| Beta | 1.55 |
| RSI | 42.78 |
|---|
| Insider ownership | N/A |
|---|---|
| Inst. ownership | N/A |
| Shares outst. | 63.480M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 9.27% |
| Short ratio | 7.17 |
| Dividend | $0.00 |
|---|---|
| Dividend yield | 0.00% |
| Payout ratio | 0.00% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 20 Jun 2024 |
Friday, 3 May 2024
|
|
| How Novo-Catalent Deal Affects Halozyme ? | |
Sunday, 10 March 2024
|
|
| Avid Bioservices Inc Releases Preliminary Q3 Financial Results | |
Friday, 1 December 2023
|
|
| Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 | |
Tuesday, 24 October 2023
|
|
| Does Avid Bioservices Have Potential For 200-400% Returns Over the Next Few Years? | |
Thursday, 22 June 2023
|
|
| Why Shares of Avid Bioservices Are Dropping Thursday | |
Tuesday, 30 May 2023
|
|
| 15 Most Undervalued Growth Stocks To Buy According To Analysts | |
Monday, 24 April 2023
|
|
| Avid Bioservices Joins Elite Club Of Stocks With RS Ratings Over 90 | |
Monday, 17 April 2023
|
|
| Improved Earnings Required Before Avid Bioservices, Inc. Shares Find Their Feet | |
Tuesday, 14 March 2023
|
|
| Why Avid Bioservices Stock Is Surging Today | |
| Avid Bioservices, Inc. Q3 2023 Earnings Call Transcript | |
Thursday, 16 February 2023
|
|
| Is Avid Bioservices a Good Investment Opportunity? | |
Friday, 9 December 2022
|
|
| Avid Bioservices, Inc. Q2 2023 Earnings Call Transcript | |
Monday, 10 October 2022
|
|
| TOMI to Install Custom Engineered Integrated iHP System in Avid Bioservices, Inc. Viral Vector Manufacturing Facility in California - Yahoo Finance | |
Tuesday, 6 September 2022
|
|
| Avid Bioservices, Inc. Q1 2023 Earnings Call Transcript | |
Thursday, 18 August 2022
|
|
| Is Avid Bioservices a Worthy Investment Pick? | |
Tuesday, 8 March 2022
|
|
| Avid Bioservices, Inc. Q3 2022 Earnings Call Transcript | |
Sunday, 27 February 2022
|
|
| Is Avid Bioservices A Smart Long-Term Buy? | |
Thursday, 3 February 2022
|
|
| Redwood Investments, LLC Buys Asbury Automotive Group Inc, Avid Bioservices Inc, SiTime Corp, ... | |
Friday, 7 January 2022
|
|
| Future Financial Wealth Managment LLC Buys The Energy Select Sector SPDR Fund, Global X U.S. ... | |
Tuesday, 7 December 2021
|
|
| Avid Bioservices, inc Q2 2022 Earnings Call Transcript | |
| Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2021 and Recent Developments - Yahoo Finance | |
Monday, 6 December 2021
|
|
| 15 Best Stocks to Buy for 2022 According to Analysts | |
Tuesday, 26 October 2021
|
|
| Why Avid Bioservices Stock Surged 14% Today | |
Tuesday, 20 July 2021
|
|
| Hedge Funds Aren’t Crazy About Avid Bioservices, Inc. Anymore | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Mark R Ziebell V. P. and General Counsel | Sale 30 Apr 2024 | $12,158 |
| Richard A. Richieri Chief Operations Officer | Sale 30 Apr 2024 | $8,244 |
| Matthew R. Kwietniak Chief Commercial Officer | Sale 30 Apr 2024 | $9,124 |
| Daniel R Hart Chief Financial Officer | Sale 30 Apr 2024 | $20,912 |
| Nicholas Stewart Green President and CEO | Sale 30 Apr 2024 | $87,039 |
| Matthew R. Kwietniak Chief Commercial Officer | Option 11 Apr 2024 | $4,616 |
| Mark R Ziebell V. P. and General Counsel | Option 9 Apr 2024 | $23,066 |
| Richard A. Richieri Chief Operations Officer | Option 9 Apr 2024 | $19,888 |
| Matthew R. Kwietniak Chief Commercial Officer | Option 9 Apr 2024 | $18,205 |
| Daniel R Hart Chief Financial Officer | Option 9 Apr 2024 | $41,285 |
| Nicholas Stewart Green President and CEO | Option 9 Apr 2024 | $164,486 |
Powered by
Robintrack.
Price target
Current $7.44
Average $11.33
Low $11
High $12
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | -100.00% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Nicholas Stewart Green B.Sc., MBA (56) Pres, CEO, and Director | 56 | $1,545,522 | |
| Mark Ziebell (56) Vice President, General Counsel, and Corporate Secretary since 2012 | 56 | 2012 | $1,085,620 |
| Daniel R. Hart (48) Chief Financial Officer | 48 | $899,280 | |
| Daniel Hart (46) Chief Financial Officer since 2018 | 46 | 2018 | $842,143 |
| Richard Hancock (61) Director since 2020 | 61 | 2020 | $774,947 |
| Mark R. Ziebell J.D. (57) VP, Gen. Counsel, and Corp. Sec. | 57 | $707,747 | |
| Catherine Mackey (64) Independent Director since 2019 | 64 | 2019 | $280,234 |
| Richard Richieri (51) Chief Operations Officer since 2019 | 51 | 2019 | $223,558 |
| Joseph Carleone (74) Independent Non-Executive Chairman of the Board since 2017 | 74 | 2017 | $187,482 |
| Gregory Sargen (55) Independent Director since 2017 | 55 | 2017 | $174,982 |
| Patrick Walsh (59) Independent Director since 2017 | 59 | 2017 | $174,606 |
| Mark Bamforth (57) Independent Director since 2017 | 57 | 2017 | $167,482 |
| Stephanie Diaz | 2020 | ||
| Timothy Compton | 2020 | ||
| Nicholas Green (56) President, Chief Executive Officer, and Director since 2020 | 56 | 2020 | |
| Prof. Alan J. Schroit | |||
| Dr. Harold F. Dvorak | |||
| Tracy L. Kinjerski | |||
| Dr. Shelley P. M. Fussey (55) VP of Intellectual Property | 55 | ||
| Matthew Kwietniak | |||
| Lorna Larson | |||
| Richard Richieri (56) Chief Operations Officer | 56 |
avid bioservices, a subsidiary of peregrine pharmaceuticals, inc. (nasdaq: pphm), is a unique contract manufacturing organization ("cmo") partner dedicated to the development and production of monoclonal antibodies, recombinant proteins and enzymes produced in mammalian cell culture. our extensive experience at all stages of development enables us to provide comprehensive development, manufacturing and support services to navigate a biologic from concept to commercialization.
- Health Care > Biotechnology
- Avid Bioservices Inc, 2642 Michelle Drive, Tustin 92780, United States
- 714 508 6100
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Irregular | Annual dividend | +0.00% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 0.00% | Growth period | N/A |
| Last dividend date | Yield 3 years | 0.00% | Growth 3 years | +0.00% | |
| Last dividend | Yield 5 years | 0.00% | Growth 5 years | -100.00% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Dec 2023 | 30 Sep 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $30.708 | $31.424 | |||
| Short term investments | |||||
| Net receivables | $18.538 | $13.379 | |||
| Inventory | $34.568 | $38.583 | |||
| Total current assets | $103.589 | $104.205 | |||
| Long term investments | |||||
| Property, plant & equipment | $229.085 | $229.147 | |||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | $351.638 | $350.437 | |||
| Total investments | |||||
| Total assets | $455.227 | $454.642 | |||
| Current liabilities | |||||
| Accounts payable | $19.514 | $22.784 | |||
| Deferred revenue | $52.945 | $46.437 | |||
| Short long term debt | $142.731 | $1.263 | |||
| Total current liabilities | $222.887 | $76.937 | |||
| Long term debt | $52.17 | $194.03 | |||
| Total noncurrent liabilities | $52.17 | $194.03 | |||
| Total debt | $194.901 | $195.293 | |||
| Total liabilities | $275.057 | $270.967 | |||
| Stockholders' equity | |||||
| Retained earnings | -$448.767 | -$442.419 | |||
| Other stockholder equity | |||||
| Total stockholder equity | $180.17 | $183.675 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $38.892 | $126.516 | ||
| Short term investments | ||||
| Net receivables | $18.298 | $20.547 | ||
| Inventory | $43.908 | $26.062 | ||
| Total current assets | $112.451 | $180.023 | ||
| Long term investments | ||||
| Property, plant & equipment | $220.141 | $129.761 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $338.603 | $249.82 | ||
| Total investments | ||||
| Total assets | $451.054 | $429.843 | ||
| Current liabilities | ||||
| Accounts payable | $24.593 | $9.504 | ||
| Deferred revenue | $37.352 | $53.798 | ||
| Short long term debt | $1.358 | $2.969 | ||
| Total current liabilities | $73.709 | $75.761 | ||
| Long term debt | $187.875 | $179.556 | ||
| Total noncurrent liabilities | $187.875 | $179.556 | ||
| Total debt | $189.233 | $182.525 | ||
| Total liabilities | $261.584 | $255.317 | ||
| Stockholders' equity | ||||
| Retained earnings | -$430.817 | -$431.377 | ||
| Other stockholder equity | ||||
| Total stockholder equity | $189.47 | $174.526 | ||
Income statement
| (in millions USD) | 31 Dec 2023 | 30 Sep 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $33.815 | $25.395 | |||
| Cost of revenue | $31.432 | $30.06 | |||
| Gross profit | $2.383 | -$4.665 | |||
| Operating activities | |||||
| Research & development | |||||
| Selling, general & administrative | $6.382 | $6.557 | |||
| Total operating expenses | $6.382 | $6.557 | |||
| Operating income | -$3.999 | -$11.222 | |||
| Income from continuing operations | |||||
| EBIT | -$6.183 | -$11.082 | |||
| Income tax expense | -$1.052 | -$2.378 | |||
| Interest expense | $0.875 | $0.805 | |||
| Net income | |||||
| Net income | -$6.006 | -$9.509 | |||
| Income (for common shares) | -$6.006 | -$9.509 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $149.266 | $119.597 | ||
| Cost of revenue | $117.786 | $82.949 | ||
| Gross profit | $31.48 | $36.648 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $27.879 | $21.226 | ||
| Total operating expenses | $27.879 | $21.226 | ||
| Operating income | $3.601 | $15.422 | ||
| Income from continuing operations | ||||
| EBIT | $4.603 | $15.341 | ||
| Income tax expense | $1.443 | -$115.011 | ||
| Interest expense | $2.6 | $2.68 | ||
| Net income | ||||
| Net income | $0.56 | $127.672 | ||
| Income (for common shares) | $0.56 | $127.672 | ||
Cash flows
| (in millions USD) | 31 Dec 2023 | 30 Sep 2023 | |||
|---|---|---|---|---|---|
| Net income | -$6.006 | -$9.509 | |||
| Operating activities | |||||
| Depreciation | $2.817 | $2.784 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $2.459 | $2.466 | |||
| Total cash flows from operations | $3.687 | $6.099 | |||
| Investing activities | |||||
| Capital expenditures | -$4.488 | -$7.323 | |||
| Investments | |||||
| Total cash flows from investing | -$4.488 | -$7.323 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $0.384 | $0.12 | |||
| Net borrowings | -$0.299 | $7.28 | |||
| Total cash flows from financing | $0.085 | $7.4 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$0.716 | $6.176 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | $0.56 | $127.672 | ||
| Operating activities | ||||
| Depreciation | $7.21 | $4.48 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.978 | $7.38 | ||
| Total cash flows from operations | -$12.887 | $9.465 | ||
| Investing activities | ||||
| Capital expenditures | -$77.638 | -$56.411 | ||
| Investments | ||||
| Total cash flows from investing | -$77.638 | -$56.411 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.406 | $3.359 | ||
| Net borrowings | -$0.505 | -$0.162 | ||
| Total cash flows from financing | $2.901 | $3.197 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$87.624 | -$43.749 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Palisade Capital Management, L.P. |
+116.79%
|
2,172,832 | $14,557,974 |
| 2024 Q1 | State Street Corp |
+22.24%
|
5,848,167 | $39,182,719 |
| 2024 Q1 | Russell Investments |
-99.96%
|
176 | $1,179 |
| 2024 Q1 | Schonfeld Strategic Advisors |
+666.20%
|
500,502 | $3,353,363 |
| 2024 Q1 | Boothbay Fund Management |
Opened
|
385,308 | $2,581,564 |
| 2024 Q1 | Wellington Management Group LL.P. |
+22.68%
|
1,814,201 | $12,155,148 |
| 2024 Q1 | Kennedy Capital Management |
+66.44%
|
597,089 | $4,000,496 |
| 2024 Q1 | Stephens Inc ar/ |
+106.74%
|
323,195 | $2,165,407 |
| 2024 Q1 | State Of Wisconsin Investment Board |
+151.87%
|
253,687 | $1,699,703 |
| 2024 Q1 | Two Sigma Advisers, L.P. |
+81.82%
|
328,450 | $2,200,615 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| State Street Corp | 9.21% | 5,848,167 | |
| Ranger Investment Management, L.P. | 3.58% | 2,272,194 | |
| Palisade Capital Management, L.P. | 3.42% | 2,172,832 | |
| Wellington Management Group LL.P. | 2.86% | 1,814,201 | |
| Punch & Associates Investment Management, Inc | 1.87% | 1,186,639 | |
| Aristotle Capital Boston | 1.15% | 729,580 | |
| Northern Trust Corp | 1.08% | 687,183 | |
| Kennedy Capital Management | 0.94% | 597,089 | |
| Schonfeld Strategic Advisors | 0.79% | 500,502 | |
| Parkman Healthcare Partners | 0.72% | 453,952 |
Sign up